TIGIT is a key inhibitory checkpoint receptor in lymphoma.

Journal for immunotherapy of cancer(2023)

Cited 2|Views18
No score
Abstract
These results provide rationale for clinical investigation of TIGIT and PD-1 blockade in lymphomas, including DLBCL.
More
Translated text
Key words
key inhibitory checkpoint receptor
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined